Results 61 to 70 of about 1,680 (126)

Remarkable Prolongation of Irreversible APTT and Non‐Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review

Journal of Clinical Laboratory Analysis, Volume 40, Issue 2, January 2026.
Patient with a bladder cancer history presented was diagnosed with Acquired hemophilia A (AHA) according to imaging findings and laboratory tests. The parameters returned to normal after treatment of methylprednisolone and cyclophosphamide. With the recurrence of AHA, the patient was finally confirmed to have liver metastases.
Ke‐Han Zhang, Song‐Song Lu, Pei‐Liang Gao, Xue‐Ying Fu, Gui‐Ying Dong   +4 more
wiley   +1 more source

Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review

Clinical and Applied Thrombosis/Hemostasis
Background Emicizumab, a bispecific factor VIII mimetic antibody, was approved in 2018 for bleeding prophylaxis in congenital hemophilia A with or without inhibitors.
Ghachem Ikbel MD, Baccouche Hela MD, Kaabar Mohamed Yassine MD, Khemiri Hamida MD, Ben Salem Kamel MD   +4 more
doaj   +1 more source

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis

Haematologica
Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against factor VIII (FVIII). Emicizumab mimics the activity of FVIIIa restoring thrombin generation.
Fabius J. Pelzer, Ella I. Ertekin, Olga Oleshko, Annika Klingberg, Paul Knöbl, Christian Pfrepper, Richard Greil, Johannes Oldenburg, Ulrich J. Sachs, Wolfgang Miesbach, Karolin Trautmann-Grill, Katharina Holstein, Hermann Eichler, Patrick Möhnle, Christina Hart, Robert Klamroth, Andreas Tiede, Sonja Werwitzke   +17 more
doaj   +1 more source

A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children

The Journal of Haemophilia Practice
The introduction of emicizumab as prophylactic subcutaneous (SC) administered treatment for people with haemophilia A has revolutionised its treatment and care; SC injection and the infrequent treatment intervals that can be achieved with emicizumab ...
Birkedal Maj Friberg
doaj   +1 more source

A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors

Case Reports in Dentistry
Haemophilia A is an inherited X-linked bleeding disorder caused by Factor VIII deficiency; approximately 30% of the patients with haemophilia A develop inhibitors against Factor VIII.
Miki Zaizen, Takahiro Yagyuu, Sachiko Yata, Hiroshi Nakamura, Mitsuhiko Imada, Nobuhiro Yamakawa   +5 more
doaj   +1 more source

Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII

Research and Practice in Thrombosis and Haemostasis
Background: The incidence of cardiovascular diseases is increasing in persons with hemophilia A (HA). Therefore, anticoagulant therapy based on direct oral anticoagulants (DOACs) may be needed, despite the bleeding risk.
Sylvain Lamoine, Vincent Jury, Virginie Fourneyron, Jonathan Douxfils, Dorian Teissandier, Laurie Talon, Thomas Sinegre, Aurélien Lebreton   +7 more
doaj   +1 more source

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Therapeutics and Clinical Risk Management, 2020
Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation ...
Linari S, Castaman G
doaj  

HINODE study: haemophilia A in infancy and newborns – protocol for a prospective, multicentre, observational study evaluating the coagulation potential and safety of emicizumab prophylaxis

BMJ Open
Introduction Emicizumab prophylaxis is approved for people of all ages with haemophilia A (HA) including infants and children. Although previous studies have demonstrated the efficacy and tolerability of emicizumab in infants with HA, real-world data on ...
Shouichi Ohga, Hirosuke Inoue, Keiji Nogami, Masahiro Takeyama, Masataka Ishimura, Daisuke Nosaka, Keisuke Iwasaki, Chika Mitsui   +7 more
doaj   +1 more source

Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests

Romanian Journal of Laboratory Medicine
This study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A.
Brinza Melen, Uscatescu Valentina, Hemcinschi Mihai, Chiriac Elisabeta, Gherghe Georgiana, Coriu Daniel   +5 more
doaj   +1 more source

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj